Cyteir Therapeutics, Inc.
SEC CIK 1662244 · CYT · last insider filing 2024-03-25
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Renschler Markus MD | Director · See Remarks | filed 2021 - 2024 |
| George Jean | Director | filed 2021 - 2024 |
| Sands Stephen H. | Director | filed 2022 - 2024 |
| Thero John F | Director | filed 2022 - 2024 |
| Zakrzewski Joseph S | Director | filed 2021 - 2024 |
| Molineaux Susan | Director | filed 2021 - 2023 |
| Humphrey Jeffrey | Director | filed 2021 - 2023 |
| Bracken Racquel | Director | filed 2021 - 2023 |
| Romberger Timothy | Director | filed 2021 - 2023 |
| Naesens Janwillem | Director | filed 2021 - 2022 |
| Hong Karen | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Gaiero David G | Vice President, Finance | filed 2021 - 2024 |
| Veness Adam M | General Counsel | filed 2022 - 2023 |
| Gengos Andrew | Chief Business Officer | filed 2021 - 2022 |
| Secrist John Paul | Chief Scientific Officer | filed 2021 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.